Zydus Lifesciences secures USFDA approval to sell generic leukaemia tablets

Share it

Shares of Zydus Lifesciences Ltd ended at ₹887.95, up by ₹16.15, or 1.85%, on the BSE.

Leave a Comment

Your email address will not be published. Required fields are marked *